KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Thermo Fisher Scientific (TMO) Cash & Equivalents (2016 - 2025)

Thermo Fisher Scientific's Cash & Equivalents history spans 17 years, with the latest figure at $9.9 billion for Q4 2025.

  • For the quarter ending Q4 2025, Cash & Equivalents rose 145.75% year-over-year to $9.9 billion, compared with a TTM value of $9.9 billion through Dec 2025, up 145.75%, and an annual FY2025 reading of $9.9 billion, up 145.75% over the prior year.
  • Cash & Equivalents for Q4 2025 was $9.9 billion at Thermo Fisher Scientific, up from $2.0 billion in the prior quarter.
  • The five-year high for Cash & Equivalents was $12.0 billion in Q4 2021, with the low at $1.9 billion in Q3 2022.
  • Average Cash & Equivalents over 5 years is $5.4 billion, with a median of $4.6 billion recorded in 2024.
  • Year-over-year, Cash & Equivalents tumbled 75.73% in 2022 and then soared 145.75% in 2025.
  • Tracing TMO's Cash & Equivalents over 5 years: stood at $4.5 billion in 2021, then skyrocketed by 90.4% to $8.5 billion in 2022, then fell by 5.24% to $8.1 billion in 2023, then plummeted by 50.37% to $4.0 billion in 2024, then surged by 145.75% to $9.9 billion in 2025.
  • Per Business Quant, the three most recent readings for TMO's Cash & Equivalents are $9.9 billion (Q4 2025), $2.0 billion (Q3 2025), and $4.6 billion (Q2 2025).